Claims for Patent: 9,872,895

Summary for Patent: 9,872,895

Title:	TLR5 ligands, therapeutic methods, and compositions related thereto
Abstract:	The disclosure relates to antiviral therapeutic methods and related compositions. In certain embodiments, the disclosure relates to methods of treating or preventing a viral infection by administering a pharmaceutical composition comprising a TLR5 ligand, such as a flagellin, to a subject in need thereof.
Inventor(s):	Gewirtz; Andrew T. (Smyrna, GA), Zhang; Benyue (Liburn, GA)
Assignee:	Emory University (Atlanta, GA)
Application Number:	13/825,349
Patent Claims:	1. A method of treating a viral infection comprising administering an isolated flagellin in an effective amount to activate TLR5 to subject that is diagnosed with, suspected of, or exhibiting symptoms of a viral infection wherein the isolated flagellin is administered in the absence of administering a viral vaccine comprising viral nucleic acid or viral antigen. 2. The method of claim 1, wherein the isolated flagellin comprises SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, or SEQ ID NO: 12. 3. The method of claim 1, wherein the subject is a human. 4. The method of claim 1, wherein isolated flagellin is administered in combination with a second antiviral agent. 5. The method of claim 1, wherein isolated flagellin is administered in combination with abacavir, acyclovir, adefovir, amantadine, amprenavir, rintatolimod, umifenovir, atazanavir, boceprevir, cidofovir, combivir, darunavir, delavirdine, didanosine, docosanol, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, famciclovir, fomivirsen, fosamprenavir, foscarnet, fosfonet, ganciclovir, ibacitabine, imunovir, idoxuridine, imiquimod, indinavir, inosine, interferon type III, interferon type II, interferon type I, lamivudine, lopinavir, loviride, maraviroc, moroxydine, methisazone, nelfinavir, nevirapine, nexavir, oseltamivir, peginterferon alfa-2a, penciclovir, peramivir, pleconaril, podophyllotoxin, raltegravir, ribavirin, rimantadine, ritonavir, pyramidine, saquinavir, stavudine, tenofovir, tenofovir disoproxil, tipranavir, trifluridine, tromantadine, valaciclovir, valganciclovir, vicriviroc, vidarabine, viramidine zalcitabine, zanamivir, and/or zidovudine. 6. The method of claim 1, wherein the subject has a compromised immune system. 7. The method of claim 1, wherein the subject is an organ transplant recipient, undergoing hemodialysis, diagnosed with cancer, receiving an immunosuppressive drug, or diagnosed with an HIV-infection. 8. A pharmaceutical composition comprising an isolated flagellin and a second antiviral agent wherein the second antiviral agent is selected from abacavir, acyclovir, adefovir, amantadine, amprenavir, rintatolimod, umifenovir, atazanavir, boceprevir, cidofovir, combivir, darunavir, delavirdine, didanosine, docosanol, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, famciclovir, fomivirsen, fosamprenavir, foscarnet, fosfonet, ganciclovir, ibacitabine, imunovir, idoxuridine, imiquimod, indinavir, inosine, interferon type III, interferon type II, interferon type I, lamivudine, lopinavir, loviride, maraviroc, moroxydine, methisazone, nelfinavir, nevirapine, nexavir, oseltamivir, peginterferon alfa-2a, penciclovir, peramivir, pleconaril, podophyllotoxin, raltegravir, ribavirin, rimantadine, ritonavir, pyramidine, saquinavir, stavudine, tenofovir, tenofovir disoproxil, tipranavir, trifluridine, tromantadine, valaciclovir, valganciclovir, vicriviroc, vidarabine, viramidine zalcitabine, zanamivir, and zidovudine. 9. A pharmaceutical composition comprising an isolated flagellin and efavirenz, emtricitabine, and tenofovir disoproxil. 10. A pharmaceutical composition comprising an isolated flagellin and abacavir, lamivudine, and zidovudine. 11. A pharmaceutical composition comprising an isolated flagellin and emtricitabine and tenofovir disoproxil. 12. The method of claim 1, wherein the isolated flagellin is administered in combination with efavirenz, emtricitabine and tenofovir disoproxil. 13. The method of claim 1, wherein the isolated flagellin is administered in combination with abacavir, lamivudine, and zidovudine. 14. The method of claim 1, wherein isolated flagellin is administered in combination with emtricitabine and tenofovir disoproxil. 15. The method of claim 1, wherein the subject is diagnosed with a rotaviral infection. 16. The method of claim 1, wherein the subject is diagnosed with an influenza viral infection.

Details for Patent 9,872,895

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Zr Pharma& Gmbh	PEGASYS	peginterferon alfa-2a	Injection	103964	10/16/2002		2030-09-24
Zr Pharma& Gmbh	PEGASYS	peginterferon alfa-2a	Injection	103964	01/07/2004		2030-09-24
Zr Pharma& Gmbh	PEGASYS	peginterferon alfa-2a	Injection	103964	09/29/2011		2030-09-24